Shots:
- The Chinese NMPA has approved Pecondle (picankibart) for the treatment of mod. to sev. plaque psoriasis (PsO) in adults who are candidates for systematic therapy
- Approval was supported by the P-III (CLEAR-1) trial in Chinese pts with mod. to sev. PsO, where picankibart demonstrated significantly higher PASI 90 (1EP; 80.3% vs 2%) & sPGA 0/1 (93.5% vs 13.1%) responses at Wk. 16 compared to PBO
- At Wk. 52, PASI 90 & sPGA 0/1 responses remained high across 100 & 200mg Q12W groups, with benefits also seen in PASI 75, PASI 100, sPGA 0, DLQI 0/1 & in special areas, incl. scalp, nail, palmoplantar & perineal regions
Ref: PR newswire | Image: Innovent Biologics | Press Release
Related News:- Innovent Biologics Reports P-III (GLORY-2) Trial Data on Mazdutide for Obesity
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
